![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NAV2 |
Gene summary for NAV2 |
![]() |
Gene information | Species | Human | Gene symbol | NAV2 | Gene ID | 89797 |
Gene name | neuron navigator 2 | |
Gene Alias | HELAD1 | |
Cytomap | 11p15.1 | |
Gene Type | protein-coding | GO ID | GO:0001976 | UniProtAcc | A7E2D6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89797 | NAV2 | P36T-E | Human | Esophagus | ESCC | 1.11e-06 | 3.17e-01 | 0.1187 |
89797 | NAV2 | P37T-E | Human | Esophagus | ESCC | 2.52e-13 | 3.53e-01 | 0.1371 |
89797 | NAV2 | P44T-E | Human | Esophagus | ESCC | 2.28e-04 | 1.94e-01 | 0.1096 |
89797 | NAV2 | P47T-E | Human | Esophagus | ESCC | 8.59e-06 | 1.27e-01 | 0.1067 |
89797 | NAV2 | P48T-E | Human | Esophagus | ESCC | 5.61e-11 | 2.76e-01 | 0.0959 |
89797 | NAV2 | P49T-E | Human | Esophagus | ESCC | 1.09e-02 | 3.29e-01 | 0.1768 |
89797 | NAV2 | P52T-E | Human | Esophagus | ESCC | 4.75e-15 | 3.70e-01 | 0.1555 |
89797 | NAV2 | P54T-E | Human | Esophagus | ESCC | 7.41e-04 | 1.31e-01 | 0.0975 |
89797 | NAV2 | P56T-E | Human | Esophagus | ESCC | 4.60e-10 | 1.45e+00 | 0.1613 |
89797 | NAV2 | P61T-E | Human | Esophagus | ESCC | 3.43e-05 | 1.48e-01 | 0.099 |
89797 | NAV2 | P65T-E | Human | Esophagus | ESCC | 1.94e-07 | 2.04e-01 | 0.0978 |
89797 | NAV2 | P75T-E | Human | Esophagus | ESCC | 4.69e-02 | 1.03e-01 | 0.1125 |
89797 | NAV2 | P76T-E | Human | Esophagus | ESCC | 2.54e-12 | 3.01e-01 | 0.1207 |
89797 | NAV2 | P79T-E | Human | Esophagus | ESCC | 1.65e-18 | 3.04e-01 | 0.1154 |
89797 | NAV2 | P82T-E | Human | Esophagus | ESCC | 2.11e-06 | 3.06e-01 | 0.1072 |
89797 | NAV2 | P107T-E | Human | Esophagus | ESCC | 2.59e-26 | 5.99e-01 | 0.171 |
89797 | NAV2 | P127T-E | Human | Esophagus | ESCC | 1.30e-02 | 6.07e-02 | 0.0826 |
89797 | NAV2 | P130T-E | Human | Esophagus | ESCC | 1.07e-26 | 5.22e-01 | 0.1676 |
89797 | NAV2 | NAFLD1 | Human | Liver | NAFLD | 6.72e-14 | 1.26e+00 | -0.04 |
89797 | NAV2 | S41 | Human | Liver | Cirrhotic | 2.45e-02 | 5.92e-01 | -0.0343 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
GO:00323922 | Liver | NAFLD | DNA geometric change | 18/1882 | 90/18723 | 3.34e-03 | 2.93e-02 | 18 |
GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:00325081 | Liver | HCC | DNA duplex unwinding | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
GO:0007626 | Lung | AIS | locomotory behavior | 31/1849 | 179/18723 | 1.39e-03 | 1.70e-02 | 31 |
GO:00030731 | Lung | MIAC | regulation of systemic arterial blood pressure | 12/967 | 96/18723 | 3.86e-03 | 4.71e-02 | 12 |
GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
GO:003239221 | Oral cavity | EOLP | DNA geometric change | 21/2218 | 90/18723 | 1.63e-03 | 1.09e-02 | 21 |
GO:003250812 | Oral cavity | EOLP | DNA duplex unwinding | 19/2218 | 84/18723 | 3.84e-03 | 2.13e-02 | 19 |
GO:003239231 | Oral cavity | NEOLP | DNA geometric change | 19/2005 | 90/18723 | 2.81e-03 | 1.73e-02 | 19 |
GO:003250821 | Oral cavity | NEOLP | DNA duplex unwinding | 18/2005 | 84/18723 | 3.02e-03 | 1.84e-02 | 18 |
GO:00323924 | Prostate | BPH | DNA geometric change | 26/3107 | 90/18723 | 2.46e-03 | 1.33e-02 | 26 |
GO:00325082 | Prostate | BPH | DNA duplex unwinding | 24/3107 | 84/18723 | 4.13e-03 | 2.04e-02 | 24 |
GO:003239212 | Prostate | Tumor | DNA geometric change | 27/3246 | 90/18723 | 2.15e-03 | 1.22e-02 | 27 |
GO:003250811 | Prostate | Tumor | DNA duplex unwinding | 25/3246 | 84/18723 | 3.47e-03 | 1.79e-02 | 25 |
GO:00323927 | Skin | AK | DNA geometric change | 23/1910 | 90/18723 | 2.53e-05 | 4.54e-04 | 23 |
GO:00325085 | Skin | AK | DNA duplex unwinding | 21/1910 | 84/18723 | 7.93e-05 | 1.09e-03 | 21 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAV2 | SNV | Missense_Mutation | c.4325G>T | p.Ser1442Ile | p.S1442I | Q8IVL1 | protein_coding | deleterious(0.02) | benign(0.229) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
NAV2 | SNV | Missense_Mutation | rs376137371 | c.1996N>A | p.Gly666Arg | p.G666R | Q8IVL1 | protein_coding | tolerated(0.07) | possibly_damaging(0.648) | TCGA-A8-A08C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NAV2 | SNV | Missense_Mutation | c.6274N>G | p.Arg2092Gly | p.R2092G | Q8IVL1 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
NAV2 | SNV | Missense_Mutation | c.4819N>G | p.Phe1607Val | p.F1607V | Q8IVL1 | protein_coding | deleterious(0) | benign(0.051) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
NAV2 | SNV | Missense_Mutation | rs141984254 | c.4319C>G | p.Ser1440Cys | p.S1440C | Q8IVL1 | protein_coding | tolerated(0.08) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NAV2 | SNV | Missense_Mutation | c.6425G>C | p.Arg2142Pro | p.R2142P | Q8IVL1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NAV2 | SNV | Missense_Mutation | rs751945616 | c.6098N>T | p.Ser2033Phe | p.S2033F | Q8IVL1 | protein_coding | deleterious(0.05) | possibly_damaging(0.543) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NAV2 | SNV | Missense_Mutation | c.2063A>G | p.Asn688Ser | p.N688S | Q8IVL1 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A18N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NAV2 | SNV | Missense_Mutation | c.1889G>A | p.Gly630Asp | p.G630D | Q8IVL1 | protein_coding | tolerated(0.14) | benign(0.146) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
NAV2 | SNV | Missense_Mutation | c.5563N>T | p.His1855Tyr | p.H1855Y | Q8IVL1 | protein_coding | tolerated(0.4) | probably_damaging(0.968) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |